Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ethinylestradiol + drospirenone (Fapasa)
- Development stage
- Unknown
- Lead developer
- FA.PA.SA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Brunelle is a combined oral contraceptive (COC) containing the synthetic estrogen ethinylestradiol and the fourth-generation progestin drospirenone. Marketed by FA.PA.SA (part of the Adium group) in Latin American regions such as Paraguay, it is primarily used for the prevention of pregnancy. The medication works by suppressing the release of gonadotropins (FSH and LH), which inhibits ovulation, while also altering cervical mucus and the endometrium to prevent fertilization and implantation. Drospirenone is unique among synthetic progestins for its anti-mineralocorticoid and anti-androgenic properties, which can help reduce estrogen-related water retention and treat androgen-dependent conditions like moderate acne vulgaris and premenstrual dysphoric disorder (PMDD).
- Brand names
- Brunelle
- Other names
- ethinylestradiol/drospirenonedrospirenone/ethinylestradiol
02
Targets
AR (Adrenergic receptors)PR (Progesterone receptor)MR (Mineralocorticoid receptor)ER (Estrogen receptor)
Beyond the preview
Go deeper on ethinylestradiol + drospirenone (Fapasa).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ethinylestradiol + drospirenone (Fapasa).